# Evidence sheet: added ribociclib × invasive disease-free survival — NATALEE interim and final results Verdict 2931 · Evidence Check Stored-material review date: Not recorded Original evidence cut-off: 2026-08-26 Review-criteria version: 1.0 Public page/material preparation date: 2026-10-10 Clinical papers were not read directly; existing review summaries were checked. No new clinical-literature search was performed. Unverified does not mean that research is absent or that there is no effect. ## Assessment scope - Population: Stage 2 or 3 HR-positive, HER2-negative early breast cancer; original NATALEE eligibility and baseline details unread - Ingredient, formulation and route: Historical study exposure to ribociclib plus endocrine therapy; no treatment-selection recommendation - Dose: The original 400 mg, 3 weeks on/1 week off, 3 years and population-specific goserelin are preserved as historical stored-summary records; no dose, administration or suitability instructions are created - Comparator: Endocrine therapy alone; other-drug trials contrast within-class results and are not direct comparisons between drugs - Measured outcome: STEEP v1.0 iDFS improvement; original interim and final effects distinguished from immature OS - Duration: Distinguishing 3-year iDFS estimates, 3-year planned exposure and final median follow-up of 33.3 months; OS-specific follow-up and maturity details unread - Questions outside this scope: Converting composite iDFS events to OS, cure or permanent prevention; Adding interim or final reports and other drugs as independent replication of ribociclib; Combining 3-year estimates, planned exposure and median follow-up of 33.3 months; Copying effects of other drugs into ribociclib OS values; Recommendations on treatment, dose, monitoring or suitability ## Checklist items ### N01 · Are the original subclaim and grade distinguished from the parent judgment context? Verification status: Partly verified Reading scope: Summary read; external materials not read - Current findings: The selected existing claim is ‘Improved invasive disease-free survival’, with subclaim grade B and the note that one large trial crossed its prespecified boundary. The parent is B, 76 points and Caution. - Why unverified: Only the relevant information in the stored summary is recorded; detailed original materials remain unread and review of existing content remains incomplete. Absent subclaim score, status and axes are not filled with parent values. No new judgment, blanket D grade or independence certification is provided. - Reason for missing information: Absent subclaim score, status and axes are not filled with parent values. No new judgment, blanket D grade or independence certification is provided. - Required materials and conditions: Separate preservation of the selected question, grade and note and the original parent judgment - Materials to obtain first: Absent subclaim score, status and axes are not filled with parent values. No new judgment, blanket D grade or independence certification is provided. - Further research: Link additional materials separately to the selected question and the parent context. - Conditions for verification: Separate preservation of the selected question, grade and note and the original parent judgment - Why this condition is needed: An individual preparation condition recording the selected claim, comparison, endpoint, denominator, timing and interpretation boundaries - Application exceptions: Unread external materials, other drugs or questions, and outcomes outside the scope do not substitute for fulfillment, zero effect or safety. - Remaining uncertainty: Unread, immature or unverified does not mean zero effect, zero events, safety or a new clinical certification. - Referenced methods: Improved invasive disease-free survival - Related sources: R01, R02 ### N02 · What is the actual early-breast-cancer population and scope of baseline conditions? Verification status: Partly verified Reading scope: Summary read; external materials not read - Current findings: NATALEE is an international phase 3 trial comparing added ribociclib in stage 2 or 3 HR-positive, HER2-negative early breast cancer. - Why unverified: Only the relevant information in the stored summary is recorded; detailed original materials remain unread and review of existing content remains incomplete. The summary lacks details of nodal status, detailed risk eligibility, baseline treatment, population composition and original group denominators. Findings are not extended to metastatic cancer or other stages or types. - Reason for missing information: The summary lacks details of nodal status, detailed risk eligibility, baseline treatment, population composition and original group denominators. Findings are not extended to metastatic cancer or other stages or types. - Required materials and conditions: Original eligibility, HR/HER2, stage, sex, baseline characteristics and denominators - Materials to obtain first: The summary lacks details of nodal status, detailed risk eligibility, baseline treatment, population composition and original group denominators. Findings are not extended to metastatic cancer or other stages or types. - Further research: Obtain original eligibility, baseline, previous-treatment and group-specific participant materials. - Conditions for verification: Original eligibility, HR/HER2, stage, sex, baseline characteristics and denominators - Why this condition is needed: An individual preparation condition recording the selected claim, comparison, endpoint, denominator, timing and interpretation boundaries - Application exceptions: Unread external materials, other drugs or questions, and outcomes outside the scope do not substitute for fulfillment, zero effect or safety. - Remaining uncertainty: Unread, immature or unverified does not mean zero effect, zero events, safety or a new clinical certification. - Referenced methods: Improved invasive disease-free survival - Related sources: R01, R02 ### N03 · What is the actual comparison between added treatment and endocrine therapy alone? Verification status: Partly verified Reading scope: Summary read; external materials not read - Current findings: Ribociclib plus endocrine therapy was compared with endocrine therapy alone. Existing topic classifications preserve aromatase inhibitors and endocrine therapy. - Why unverified: Only the relevant information in the stored summary is recorded; detailed original materials remain unread and review of existing content remains incomplete. This is not converted to ribociclib alone, ineffectiveness of endocrine therapy or direct superiority over other drugs. Original tables on specific endocrine drugs, concomitant treatment and exposure changes have not been read. - Reason for missing information: This is not converted to ribociclib alone, ineffectiveness of endocrine therapy or direct superiority over other drugs. Original tables on specific endocrine drugs, concomitant treatment and exposure changes have not been read. - Required materials and conditions: Original intervention and comparator, shared endocrine therapy, concomitant treatment and actual exposure - Materials to obtain first: This is not converted to ribociclib alone, ineffectiveness of endocrine therapy or direct superiority over other drugs. Original tables on specific endocrine drugs, concomitant treatment and exposure changes have not been read. - Further research: Obtain original group-specific interventions, shared endocrine therapy, concomitant treatment and changes. - Conditions for verification: Original intervention and comparator, shared endocrine therapy, concomitant treatment and actual exposure - Why this condition is needed: An individual preparation condition recording the selected claim, comparison, endpoint, denominator, timing and interpretation boundaries - Application exceptions: Unread external materials, other drugs or questions, and outcomes outside the scope do not substitute for fulfillment, zero effect or safety. - Remaining uncertainty: Unread, immature or unverified does not mean zero effect, zero events, safety or a new clinical certification. - Referenced methods: Improved invasive disease-free survival - Related sources: R01, R02 ### N04 · Are the study dose and 3-year plan distinguished from actual treatment completion? Verification status: Partly verified Reading scope: Summary read; external materials not read - Current findings: The original conditions were a study plan of 400 mg for 3 weeks on and 1 week off, repeated for 3 years. This is historical exposure preserved in the existing review summary. - Why unverified: Only the relevant information in the stored summary is recorded; detailed original materials remain unread and review of existing content remains incomplete. This does not certify that all participants completed 3 years or advise individuals on dose, schedule or treatment. Distributions of actual treatment, adherence, discontinuation and dose reduction have not been read. - Reason for missing information: This does not certify that all participants completed 3 years or advise individuals on dose, schedule or treatment. Distributions of actual treatment, adherence, discontinuation and dose reduction have not been read. - Required materials and conditions: Original study exposure, planned duration, actual adherence, reduction or discontinuation, and denominators - Materials to obtain first: This does not certify that all participants completed 3 years or advise individuals on dose, schedule or treatment. Distributions of actual treatment, adherence, discontinuation and dose reduction have not been read. - Further research: Obtain original plans, actual exposure, completion, discontinuation, dose reduction and denominators. - Conditions for verification: Original study exposure, planned duration, actual adherence, reduction or discontinuation, and denominators - Why this condition is needed: An individual preparation condition recording the selected claim, comparison, endpoint, denominator, timing and interpretation boundaries - Application exceptions: Unread external materials, other drugs or questions, and outcomes outside the scope do not substitute for fulfillment, zero effect or safety. - Remaining uncertainty: Unread, immature or unverified does not mean zero effect, zero events, safety or a new clinical certification. - Referenced methods: Improved invasive disease-free survival - Related sources: R01, R02 ### N05 · Is concomitant exposure in premenopausal women and men recorded separately? Verification status: Partly verified Reading scope: Summary read; external materials not read - Current findings: The existing review summary states that premenopausal women and men also received goserelin. - Why unverified: Only the relevant information in the stored summary is recorded; detailed original materials remain unread and review of existing content remains incomplete. This is not converted to a goserelin-only effect, identical exposure for everyone or individual treatment suitability. Population-specific group denominators, original effects and interactions have not been read. - Reason for missing information: This is not converted to a goserelin-only effect, identical exposure for everyone or individual treatment suitability. Population-specific group denominators, original effects and interactions have not been read. - Required materials and conditions: Population-specific concomitant treatment, original denominators, actual exposure and analyses - Materials to obtain first: This is not converted to a goserelin-only effect, identical exposure for everyone or individual treatment suitability. Population-specific group denominators, original effects and interactions have not been read. - Further research: Obtain population-specific shared or added exposure, denominators and prespecified-analysis materials. - Conditions for verification: Population-specific concomitant treatment, original denominators, actual exposure and analyses - Why this condition is needed: An individual preparation condition recording the selected claim, comparison, endpoint, denominator, timing and interpretation boundaries - Application exceptions: Unread external materials, other drugs or questions, and outcomes outside the scope do not substitute for fulfillment, zero effect or safety. - Remaining uncertainty: Unread, immature or unverified does not mean zero effect, zero events, safety or a new clinical certification. - Referenced methods: Improved invasive disease-free survival - Related sources: R01, R02 ### N06 · What are the 5,101 randomized participants and outcome-specific denominators or risk sets? Verification status: Partly verified Reading scope: Summary read; external materials not read - Current findings: NATALEE randomized 5,101 participants; the existing review summary records 1:1 allocation and ITT analysis. - Why unverified: Only the relevant information in the stored summary is recorded; detailed original materials remain unread and review of existing content remains incomplete. No new group counts, total events, dropout rates or risk sets are calculated. The original ITT description alone does not newly certify outcome-specific missingness or complete follow-up. - Reason for missing information: No new group counts, total events, dropout rates or risk sets are calculated. The original ITT description alone does not newly certify outcome-specific missingness or complete follow-up. - Required materials and conditions: Randomization, original group counts, ITT, follow-up and outcome-specific denominators - Materials to obtain first: No new group counts, total events, dropout rates or risk sets are calculated. The original ITT description alone does not newly certify outcome-specific missingness or complete follow-up. - Further research: Obtain original participant flow, group allocation, ITT, risk sets, censoring and denominators. - Conditions for verification: Randomization, original group counts, ITT, follow-up and outcome-specific denominators - Why this condition is needed: An individual preparation condition recording the selected claim, comparison, endpoint, denominator, timing and interpretation boundaries - Application exceptions: Unread external materials, other drugs or questions, and outcomes outside the scope do not substitute for fulfillment, zero effect or safety. - Remaining uncertainty: Unread, immature or unverified does not mean zero effect, zero events, safety or a new clinical certification. - Referenced methods: Improved invasive disease-free survival - Related sources: R01, R02 ### N07 · Are the original roles of open-label design, central allocation and objective events distinguished? Verification status: Partly verified Reading scope: Summary read; external materials not read - Current findings: The existing review summary records a central interactive allocation system, 1:1 allocation, open-label design, objective recurrence, invasive cancer or death events, and ITT as historical B0 evidence. - Why unverified: Only the relevant information in the stored summary is recorded; detailed original materials remain unread and review of existing content remains incomplete. This is not converted into a new certification of blinding in all assessment or analysis, or absence of bias. Original procedural details have not been read externally. - Reason for missing information: This is not converted into a new certification of blinding in all assessment or analysis, or absence of bias. Original procedural details have not been read externally. - Required materials and conditions: Allocation, concealment, adjudicators, blinding and event ascertainment - Materials to obtain first: This is not converted into a new certification of blinding in all assessment or analysis, or absence of bias. Original procedural details have not been read externally. - Further research: Obtain original allocation, ascertainment, adjudication, analysis, censoring and bias materials. - Conditions for verification: Allocation, concealment, adjudicators, blinding and event ascertainment - Why this condition is needed: An individual preparation condition recording the selected claim, comparison, endpoint, denominator, timing and interpretation boundaries - Application exceptions: Unread external materials, other drugs or questions, and outcomes outside the scope do not substitute for fulfillment, zero effect or safety. - Remaining uncertainty: Unread, immature or unverified does not mean zero effect, zero events, safety or a new clinical certification. - Referenced methods: Improved invasive disease-free survival - Related sources: R01, R02 ### N08 · Are the composite iDFS events distinguished from overall survival? Verification status: Partly verified Reading scope: Summary read; external materials not read - Current findings: The original primary endpoint is STEEP v1.0 iDFS, a composite of recurrence, invasive cancer and death. The stored summary records overall-survival data as still immature. - Why unverified: Only the relevant information in the stored summary is recorded; detailed original materials remain unread and review of existing content remains incomplete. Reduction in composite events is not transferred to reduced all-cause death, longer survival time or definite cure. Original tables of individual components and all-cause deaths have not been read. - Reason for missing information: Reduction in composite events is not transferred to reduced all-cause death, longer survival time or definite cure. Original tables of individual components and all-cause deaths have not been read. - Required materials and conditions: Original STEEP definition, components, people or events, all-cause death and duration - Materials to obtain first: Reduction in composite events is not transferred to reduced all-cause death, longer survival time or definite cure. Original tables of individual components and all-cause deaths have not been read. - Further research: Obtain original STEEP definitions, component-specific events, overall survival, durations and denominators separately. - Conditions for verification: Original STEEP definition, components, people or events, all-cause death and duration - Why this condition is needed: An individual preparation condition recording the selected claim, comparison, endpoint, denominator, timing and interpretation boundaries - Application exceptions: Unread external materials, other drugs or questions, and outcomes outside the scope do not substitute for fulfillment, zero effect or safety. - Remaining uncertainty: Unread, immature or unverified does not mean zero effect, zero events, safety or a new clinical certification. - Referenced methods: Improved invasive disease-free survival - Related sources: R01, R02 ### N09 · Are the interim 3-year survival rates, HR, CI and two-sided P preserved as recorded? Verification status: Partly verified Reading scope: Summary read; external materials not read - Current findings: At interim analysis, 3-year iDFS was 90.4% versus 87.1%, HR 0.75(95% CI 0.62~0.91), two-sided P=.003. - Why unverified: Only the relevant information in the stored summary is recorded; detailed original materials remain unread and review of existing content remains incomplete. Survival rates are not converted to simple event proportions or OS values. No new absolute difference, NNT, risk ratio, reversed HR or P value is calculated. - Reason for missing information: Survival rates are not converted to simple event proportions or OS values. No new absolute difference, NNT, risk ratio, reversed HR or P value is calculated. - Required materials and conditions: Original analysis timing, 3-year estimates, HR, CI, tests and denominators - Materials to obtain first: Survival rates are not converted to simple event proportions or OS values. No new absolute difference, NNT, risk ratio, reversed HR or P value is calculated. - Further research: Obtain original estimation methods, group risk sets, censoring, denominators, CI and models. - Conditions for verification: Original analysis timing, 3-year estimates, HR, CI, tests and denominators - Why this condition is needed: An individual preparation condition recording the selected claim, comparison, endpoint, denominator, timing and interpretation boundaries - Application exceptions: Unread external materials, other drugs or questions, and outcomes outside the scope do not substitute for fulfillment, zero effect or safety. - Remaining uncertainty: Unread, immature or unverified does not mean zero effect, zero events, safety or a new clinical certification. - Referenced methods: Improved invasive disease-free survival - Related sources: R01, R02 ### N10 · Are the prespecified one-sided boundary and two-sided P distinguished? Verification status: Partly verified Reading scope: Summary read; external materials not read - Current findings: The existing review summary records two-sided P=.003 and the protocol's one-sided P<.0128 boundary, stating that the prespecified superiority boundary was crossed. - Why unverified: Only the relevant information in the stored summary is recorded; detailed original materials remain unread and review of existing content remains incomplete. Two-sided and one-sided values are not made identical, and no new test, boundary or exemption from multiplicity is certified. Original registration, planning and boundary documents have not been read. - Reason for missing information: Two-sided and one-sided values are not made identical, and no new test, boundary or exemption from multiplicity is certified. Original registration, planning and boundary documents have not been read. - Required materials and conditions: Protocol, interim analysis, test direction, alpha spending, boundary and changes - Materials to obtain first: Two-sided and one-sided values are not made identical, and no new test, boundary or exemption from multiplicity is certified. Original registration, planning and boundary documents have not been read. - Further research: Obtain original interim-analysis plans, boundaries, direction, alpha spending and change history. - Conditions for verification: Protocol, interim analysis, test direction, alpha spending, boundary and changes - Why this condition is needed: An individual preparation condition recording the selected claim, comparison, endpoint, denominator, timing and interpretation boundaries - Application exceptions: Unread external materials, other drugs or questions, and outcomes outside the scope do not substitute for fulfillment, zero effect or safety. - Remaining uncertainty: Unread, immature or unverified does not mean zero effect, zero events, safety or a new clinical certification. - Referenced methods: Improved invasive disease-free survival - Related sources: R01, R02 ### N11 · Are the final 33.3-month analysis and 226/283 events distinguished from interim values? Verification status: Partly verified Reading scope: Summary read; external materials not read - Current findings: The prespecified final analysis had median follow-up of 33.3 months, 226 versus 283 events, HR 0.749(95% CI 0.628~0.892), P=.0012. - Why unverified: Only the relevant information in the stored summary is recorded; detailed original materials remain unread and review of existing content remains incomplete. Median follow-up of 33.3 months is not equated with the time point of the 3-year survival estimate, and events from the two reports are not added. No new final 3-year rate, event total or OS result is created. - Reason for missing information: Median follow-up of 33.3 months is not equated with the time point of the 3-year survival estimate, and events from the two reports are not added. No new final 3-year rate, event total or OS result is created. - Required materials and conditions: Analysis cutoff date, follow-up statistics, events, original effects and denominators - Materials to obtain first: Median follow-up of 33.3 months is not equated with the time point of the 3-year survival estimate, and events from the two reports are not added. No new final 3-year rate, event total or OS result is created. - Further research: Obtain original analysis cutoffs, follow-up distributions, risk sets, models and event mapping. - Conditions for verification: Analysis cutoff date, follow-up statistics, events, original effects and denominators - Why this condition is needed: An individual preparation condition recording the selected claim, comparison, endpoint, denominator, timing and interpretation boundaries - Application exceptions: Unread external materials, other drugs or questions, and outcomes outside the scope do not substitute for fulfillment, zero effect or safety. - Remaining uncertainty: Unread, immature or unverified does not mean zero effect, zero events, safety or a new clinical certification. - Referenced methods: Improved invasive disease-free survival - Related sources: R01, R02 ### N12 · Are interim and final reports kept from being added as new independent confirmation? Verification status: Partly verified Reading scope: Summary read; external materials not read - Current findings: The Slamon2024 interim report and Hortobagyi2025 final report concern the same NATALEE trial. The stored summary records one confirmatory trial of ribociclib itself. - Why unverified: Only the relevant information in the stored summary is recorded; detailed original materials remain unread and review of existing content remains incomplete. The 2 reports, follow-up and two subclaim outcomes are not added as new independent trials or participants. Final independent and participant totals are not recorded. - Reason for missing information: The 2 reports, follow-up and two subclaim outcomes are not added as new independent trials or participants. Final independent and participant totals are not recorded. - Required materials and conditions: The same trial and population, follow-up reports, individual outcomes and sibling-sheet relationships - Materials to obtain first: The 2 reports, follow-up and two subclaim outcomes are not added as new independent trials or participants. Final independent and participant totals are not recorded. - Further research: Connect additional reports through original registration, population, timing and overlap relationships. - Conditions for verification: The same trial and population, follow-up reports, individual outcomes and sibling-sheet relationships - Why this condition is needed: An individual preparation condition recording the selected claim, comparison, endpoint, denominator, timing and interpretation boundaries - Application exceptions: Unread external materials, other drugs or questions, and outcomes outside the scope do not substitute for fulfillment, zero effect or safety. - Remaining uncertainty: Unread, immature or unverified does not mean zero effect, zero events, safety or a new clinical certification. - Referenced methods: Improved invasive disease-free survival - Related sources: R01, R02 ### N13 · What gaps remain in overall-survival event maturity, effects, CI, P and hierarchy? Verification status: Unverified Reading scope: Summary read; external materials not read - Current findings: The note for the longer-overall-survival subclaim states that the data remain immature. The existing review summary and safety text preserve this limitation. - Why unverified: Only the relevant information in the stored summary is recorded; detailed original materials remain unread and review of existing content remains incomplete. The 226/283 iDFS events, HR or CI are not used to fill OS events or effects. The summary lacks OS deaths, HR, CI, P, information fraction and cutoff date. Immaturity is not converted to a definite zero effect. - Reason for missing information: The 226/283 iDFS events, HR or CI are not used to fill OS events or effects. The summary lacks OS deaths, HR, CI, P, information fraction and cutoff date. Immaturity is not converted to a definite zero effect. - Required materials and conditions: Original deaths, follow-up, OS effect of interest, denominators, plans and maturity - Materials to obtain first: The 226/283 iDFS events, HR or CI are not used to fill OS events or effects. The summary lacks OS deaths, HR, CI, P, information fraction and cutoff date. Immaturity is not converted to a definite zero effect. - Further research: Obtain original OS events, denominators, follow-up, prespecified hierarchy, boundaries, models and CI. - Conditions for verification: Original deaths, follow-up, OS effect of interest, denominators, plans and maturity - Why this condition is needed: An individual preparation condition recording the selected claim, comparison, endpoint, denominator, timing and interpretation boundaries - Application exceptions: Unread external materials, other drugs or questions, and outcomes outside the scope do not substitute for fulfillment, zero effect or safety. - Remaining uncertainty: Unread, immature or unverified does not mean zero effect, zero events, safety or a new clinical certification. - Referenced methods: Improved invasive disease-free survival - Related sources: R01, R02 ### N14 · Is the original scope of iDFS improvement kept from extending to long-term survival or cure? Verification status: Partly verified Reading scope: Summary read; external materials not read - Current findings: The original note for subclaim B states that one large trial crossed its prespecified boundary. Original interim and final iDFS results are recorded. - Why unverified: Only the relevant information in the stored summary is recorded; detailed original materials remain unread and review of existing content remains incomplete. These original results do not establish overall survival, cure or permanent prevention after treatment ends. No new individual effect or application recommendation is provided. - Reason for missing information: These original results do not establish overall survival, cure or permanent prevention after treatment ends. No new individual effect or application recommendation is provided. - Required materials and conditions: Original composite endpoint, clinical components, duration and direct long-term outcomes - Materials to obtain first: These original results do not establish overall survival, cure or permanent prevention after treatment ends. No new individual effect or application recommendation is provided. - Further research: Obtain original component-specific outcomes, long-term iDFS, OS and functional outcomes separately. - Conditions for verification: Original composite endpoint, clinical components, duration and direct long-term outcomes - Why this condition is needed: An individual preparation condition recording the selected claim, comparison, endpoint, denominator, timing and interpretation boundaries - Application exceptions: Unread external materials, other drugs or questions, and outcomes outside the scope do not substitute for fulfillment, zero effect or safety. - Remaining uncertainty: Unread, immature or unverified does not mean zero effect, zero events, safety or a new clinical certification. - Referenced methods: Improved invasive disease-free survival - Related sources: R01, R02 ### N15 · Are actual exposure completion, survival follow-up and long-term persistence distinguished? Verification status: Partly verified Reading scope: Summary read; external materials not read - Current findings: The original intervention plan was 3 years, while median follow-up in the final iDFS analysis was 33.3 months; these are different time descriptions. - Why unverified: Only the relevant information in the stored summary is recorded; detailed original materials remain unread and review of existing content remains incomplete. These two durations are not combined as identical treatment or follow-up for everyone, or a persistent long-term effect after treatment ends. - Reason for missing information: These two durations are not combined as identical treatment or follow-up for everyone, or a persistent long-term effect after treatment ends. - Required materials and conditions: Planned exposure, actual completion, follow-up duration and post-discontinuation outcomes - Materials to obtain first: These two durations are not combined as identical treatment or follow-up for everyone, or a persistent long-term effect after treatment ends. - Further research: Obtain original actual exposure, follow-up, censoring and long-term outcomes after discontinuation. - Conditions for verification: Planned exposure, actual completion, follow-up duration and post-discontinuation outcomes - Why this condition is needed: An individual preparation condition recording the selected claim, comparison, endpoint, denominator, timing and interpretation boundaries - Application exceptions: Unread external materials, other drugs or questions, and outcomes outside the scope do not substitute for fulfillment, zero effect or safety. - Remaining uncertainty: Unread, immature or unverified does not mean zero effect, zero events, safety or a new clinical certification. - Referenced methods: Improved invasive disease-free survival - Related sources: R01, R02 ### N16 · Do information gaps remain for subgroups, stage or sex application, and multiplicity? Verification status: Unverified Reading scope: Summary read; external materials not read - Current findings: The original population was stage 2 or 3 HR-positive, HER2-negative disease; concomitant goserelin exposure in premenopausal women and men is recorded. - Why unverified: Only the relevant information in the stored summary is recorded; detailed original materials remain unread and review of existing content remains incomplete. No new population-specific effects, drug suitability, individual predictions or prespecified interaction results are created. Detailed subgroup plans, original denominators and multiplicity have not been read. - Reason for missing information: No new population-specific effects, drug suitability, individual predictions or prespecified interaction results are created. Detailed subgroup plans, original denominators and multiplicity have not been read. - Required materials and conditions: Prespecified subgroups, interactions, models, original denominators and effects - Materials to obtain first: No new population-specific effects, drug suitability, individual predictions or prespecified interaction results are created. Detailed subgroup plans, original denominators and multiplicity have not been read. - Further research: Obtain prespecified subgroup, interaction, denominator, CI and multiplicity materials. - Conditions for verification: Prespecified subgroups, interactions, models, original denominators and effects - Why this condition is needed: An individual preparation condition recording the selected claim, comparison, endpoint, denominator, timing and interpretation boundaries - Application exceptions: Unread external materials, other drugs or questions, and outcomes outside the scope do not substitute for fulfillment, zero effect or safety. - Remaining uncertainty: Unread, immature or unverified does not mean zero effect, zero events, safety or a new clinical certification. - Referenced methods: Improved invasive disease-free survival - Related sources: R01, R02 ### N17 · What are the other drug, trial and level of wording in PALLAS? Verification status: Partly verified Reading scope: Summary read; external materials not read - Current findings: PALLAS is summarized in the stored record as a phase 3 trial with 5,796 participants, Pfizer and cooperative study groups, and no added benefit from palbociclib. - Why unverified: Only the relevant information in the stored summary is recorded; detailed original materials remain unread and review of existing content remains incomplete. It is not used as direct replication of ribociclib or a direct comparison of superiority between drugs. Detailed PALLAS effects, CI, P, duration, eligibility and a separate citation link are absent from the existing review summary. - Reason for missing information: It is not used as direct replication of ribociclib or a direct comparison of superiority between drugs. Detailed PALLAS effects, CI, P, duration, eligibility and a separate citation link are absent from the existing review summary. - Required materials and conditions: Palbociclib population, intervention, comparison, denominators, original effects and bibliography - Materials to obtain first: It is not used as direct replication of ribociclib or a direct comparison of superiority between drugs. Detailed PALLAS effects, CI, P, duration, eligibility and a separate citation link are absent from the existing review summary. - Further research: Obtain original PALLAS reports, population, comparison, effects, duration, denominators and bibliography separately. - Conditions for verification: Palbociclib population, intervention, comparison, denominators, original effects and bibliography - Why this condition is needed: An individual preparation condition recording the selected claim, comparison, endpoint, denominator, timing and interpretation boundaries - Application exceptions: Unread external materials, other drugs or questions, and outcomes outside the scope do not substitute for fulfillment, zero effect or safety. - Remaining uncertainty: Unread, immature or unverified does not mean zero effect, zero events, safety or a new clinical certification. - Referenced methods: Improved invasive disease-free survival - Related sources: R01, R02, R04 ### N18 · Are the repeated CI, drug and original comparison scope of PENELOPE-B preserved? Verification status: Partly verified Reading scope: Summary read; external materials not read - Current findings: PENELOPE-B was a double-blind, placebo-controlled phase 3 palbociclib trial with 1,250 participants, HR 0.93(95% repeated CI 0.74~1.17), P=.525. - Why unverified: Only the relevant information in the stored summary is recorded; detailed original materials remain unread and review of existing content remains incomplete. The repeated CI is not newly certified as the same analysis as an ordinary CI, and these values do not replace ribociclib OS or iDFS. Original follow-up, eligibility and planning details have not been read. - Reason for missing information: The repeated CI is not newly certified as the same analysis as an ordinary CI, and these values do not replace ribociclib OS or iDFS. Original follow-up, eligibility and planning details have not been read. - Required materials and conditions: Original drug, double blinding, placebo, effects, repeated CI and denominators - Materials to obtain first: The repeated CI is not newly certified as the same analysis as an ordinary CI, and these values do not replace ribociclib OS or iDFS. Original follow-up, eligibility and planning details have not been read. - Further research: Obtain original repeated CI, plans, population, follow-up, denominators and effects. - Conditions for verification: Original drug, double blinding, placebo, effects, repeated CI and denominators - Why this condition is needed: An individual preparation condition recording the selected claim, comparison, endpoint, denominator, timing and interpretation boundaries - Application exceptions: Unread external materials, other drugs or questions, and outcomes outside the scope do not substitute for fulfillment, zero effect or safety. - Remaining uncertainty: Unread, immature or unverified does not mean zero effect, zero events, safety or a new clinical certification. - Referenced methods: Improved invasive disease-free survival - Related sources: R01, R02, R03 ### N19 · Are monarchE's other drug and 4-year results distinguished from NATALEE? Verification status: Partly verified Reading scope: Summary read; external materials not read - Current findings: The existing review summary records monarchE as an abemaciclib trial with 5,637 participants, 4-year rates 85.8% versus 79.4%, HR 0.664(95% CI 0.578~0.762), supported by Eli Lilly. - Why unverified: Only the relevant information in the stored summary is recorded; detailed original materials remain unread and review of existing content remains incomplete. These values do not fill ribociclib's 4-year or OS results or create a direct superiority or equivalence comparison between drugs. A separate citation link, original P value and detailed eligibility are absent from the existing review summary. - Reason for missing information: These values do not fill ribociclib's 4-year or OS results or create a direct superiority or equivalence comparison between drugs. A separate citation link, original P value and detailed eligibility are absent from the existing review summary. - Required materials and conditions: Original drug, population, duration, denominators, effects and independent relationships - Materials to obtain first: These values do not fill ribociclib's 4-year or OS results or create a direct superiority or equivalence comparison between drugs. A separate citation link, original P value and detailed eligibility are absent from the existing review summary. - Further research: Obtain original monarchE bibliography, eligibility, comparison, duration, effects and plans separately. - Conditions for verification: Original drug, population, duration, denominators, effects and independent relationships - Why this condition is needed: An individual preparation condition recording the selected claim, comparison, endpoint, denominator, timing and interpretation boundaries - Application exceptions: Unread external materials, other drugs or questions, and outcomes outside the scope do not substitute for fulfillment, zero effect or safety. - Remaining uncertainty: Unread, immature or unverified does not mean zero effect, zero events, safety or a new clinical certification. - Referenced methods: Improved invasive disease-free survival - Related sources: R01, R02, R05 ### N20 · Are different within-class results kept from becoming a class-wide effect or new independent replication? Verification status: Partly verified Reading scope: Summary read; external materials not read - Current findings: The stored summary contrasts two null palbociclib trials with positive ribociclib NATALEE and abemaciclib monarchE results, limiting generalization across drugs. - Why unverified: Only the relevant information in the stored summary is recorded; detailed original materials remain unread and review of existing content remains incomplete. Positive or null results for other drugs are not used as independent NATALEE replication, zero ribociclib effect, class-wide benefit or direct superiority. Study participants and reports are not added together. - Reason for missing information: Positive or null results for other drugs are not used as independent NATALEE replication, zero ribociclib effect, class-wide benefit or direct superiority. Study participants and reports are not added together. - Required materials and conditions: Drug-specific questions, eligibility, comparators, durations and report or participant relationships - Materials to obtain first: Positive or null results for other drugs are not used as independent NATALEE replication, zero ribociclib effect, class-wide benefit or direct superiority. Study participants and reports are not added together. - Further research: Obtain drug-specific direct questions, original eligibility, duration, comparators and overlap relationships. - Conditions for verification: Drug-specific questions, eligibility, comparators, durations and report or participant relationships - Why this condition is needed: An individual preparation condition recording the selected claim, comparison, endpoint, denominator, timing and interpretation boundaries - Application exceptions: Unread external materials, other drugs or questions, and outcomes outside the scope do not substitute for fulfillment, zero effect or safety. - Remaining uncertainty: Unread, immature or unverified does not mean zero effect, zero events, safety or a new clinical certification. - Referenced methods: Improved invasive disease-free survival - Related sources: R01, R02, R03, R04, R05 ### N21 · Are Novartis, TRIO, unreported public support and company roles distinguished? Verification status: Partly verified Reading scope: Summary read; external materials not read - Current findings: NATALEE was supported by Novartis and co-supervised by TRIO; the existing Korean article records no separate public grant as reported. - Why unverified: Only the relevant information in the stored summary is recorded; detailed original materials remain unread and review of existing content remains incomplete. TRIO supervision is not converted into certification of funding, drug supply or analytical independence. Details of drug or in-kind provision, employee authors, external analysis and writing roles are absent from the existing review summary or unread. - Reason for missing information: TRIO supervision is not converted into certification of funding, drug supply or analytical independence. Details of drug or in-kind provision, employee authors, external analysis and writing roles are absent from the existing review summary or unread. - Required materials and conditions: Cash, drugs or in-kind support, affiliations, external analysis, supervision and writing roles - Materials to obtain first: TRIO supervision is not converted into certification of funding, drug supply or analytical independence. Details of drug or in-kind provision, employee authors, external analysis and writing roles are absent from the existing review summary or unread. - Further research: Obtain original disclosures of funding, supply, affiliations, supervision, analysis and writing separately. - Conditions for verification: Cash, drugs or in-kind support, affiliations, external analysis, supervision and writing roles - Why this condition is needed: An individual preparation condition recording the selected claim, comparison, endpoint, denominator, timing and interpretation boundaries - Application exceptions: Unread external materials, other drugs or questions, and outcomes outside the scope do not substitute for fulfillment, zero effect or safety. - Remaining uncertainty: Unread, immature or unverified does not mean zero effect, zero events, safety or a new clinical certification. - Referenced methods: Improved invasive disease-free survival - Related sources: R01, R02 ### N22 · Are funding and independence information for other-drug trials kept within their original scope? Verification status: Partly verified Reading scope: Summary read; external materials not read - Current findings: Original funding information records Pfizer and cooperative study groups for PALLAS, the GBG and Pfizer development program for PENELOPE-B, and Eli Lilly for monarchE. - Why unverified: Only the relevant information in the stored summary is recorded; detailed original materials remain unread and review of existing content remains incomplete. Participation of study groups alone does not newly certify absence of company in-kind support or employee authors, or independence of external analysis. Original role details have not been read. - Reason for missing information: Participation of study groups alone does not newly certify absence of company in-kind support or employee authors, or independence of external analysis. Original role details have not been read. - Required materials and conditions: Each trial's funding, in-kind support, authors, analysis and roles - Materials to obtain first: Participation of study groups alone does not newly certify absence of company in-kind support or employee authors, or independence of external analysis. Original role details have not been read. - Further research: Obtain each trial's original support, products, affiliations, analysis and writing relationships. - Conditions for verification: Each trial's funding, in-kind support, authors, analysis and roles - Why this condition is needed: An individual preparation condition recording the selected claim, comparison, endpoint, denominator, timing and interpretation boundaries - Application exceptions: Unread external materials, other drugs or questions, and outcomes outside the scope do not substitute for fulfillment, zero effect or safety. - Remaining uncertainty: Unread, immature or unverified does not mean zero effect, zero events, safety or a new clinical certification. - Referenced methods: Improved invasive disease-free survival - Related sources: R01, R02, R04, R03, R05 ### N23 · What collection gaps remain for neutropenia, liver-related adverse events and QT prolongation? Verification status: Partly verified Reading scope: Summary read; external materials not read - Current findings: The stored safety record lists neutropenia, liver-related adverse events and QT prolongation; the parent's safety status is Caution. - Why unverified: Only the relevant information in the stored summary is recorded; detailed original materials remain unread and review of existing content remains incomplete. No new harm rates, grades, risk differences, P, CI, safety ranking or monitoring instructions are created. Original details of people or events, collection, denominators and relatedness have not been read. - Reason for missing information: No new harm rates, grades, risk differences, P, CI, safety ranking or monitoring instructions are created. Original details of people or events, collection, denominators and relatedness have not been read. - Required materials and conditions: Each harm's definition, grade, people or events, original denominators, exposure and relatedness - Materials to obtain first: No new harm rates, grades, risk differences, P, CI, safety ranking or monitoring instructions are created. Original details of people or events, collection, denominators and relatedness have not been read. - Further research: Obtain original harm types, grades, collection, group denominators, exposure, relatedness and discontinuation. - Conditions for verification: Each harm's definition, grade, people or events, original denominators, exposure and relatedness - Why this condition is needed: An individual preparation condition recording the selected claim, comparison, endpoint, denominator, timing and interpretation boundaries - Application exceptions: Unread external materials, other drugs or questions, and outcomes outside the scope do not substitute for fulfillment, zero effect or safety. - Remaining uncertainty: Unread, immature or unverified does not mean zero effect, zero events, safety or a new clinical certification. - Referenced methods: Improved invasive disease-free survival - Related sources: R01, R02 ### N24 · Are harm-related discontinuation, dose reduction, actual exposure and ITT distinguished? Verification status: Unverified Reading scope: Summary read; external materials not read - Current findings: The stored summary records planned exposure of 3 years and ITT analysis, and describes harm types. - Why unverified: Only the relevant information in the stored summary is recorded; detailed original materials remain unread and review of existing content remains incomplete. These do not support new calculations of exposure completion for everyone, discontinuation rates, adherent-participant effects or survival differences caused by harms. - Reason for missing information: These do not support new calculations of exposure completion for everyone, discontinuation rates, adherent-participant effects or survival differences caused by harms. - Required materials and conditions: Original discontinuation, dose reduction, adherence, exposure, harms and event mapping - Materials to obtain first: These do not support new calculations of exposure completion for everyone, discontinuation rates, adherent-participant effects or survival differences caused by harms. - Further research: Obtain original actual exposure, harm-related discontinuation, dose reduction, adherence, follow-up and event connections. - Conditions for verification: Original discontinuation, dose reduction, adherence, exposure, harms and event mapping - Why this condition is needed: An individual preparation condition recording the selected claim, comparison, endpoint, denominator, timing and interpretation boundaries - Application exceptions: Unread external materials, other drugs or questions, and outcomes outside the scope do not substitute for fulfillment, zero effect or safety. - Remaining uncertainty: Unread, immature or unverified does not mean zero effect, zero events, safety or a new clinical certification. - Referenced methods: Improved invasive disease-free survival - Related sources: R01, R02 ### N25 · Are rare or long-term harms and replication of harms in other drugs kept from being newly established? Verification status: Unverified Reading scope: Summary read; external materials not read - Current findings: The currently designated stored summary records some harm types and still-immature OS, while other-drug trials are used as iDFS contrasts. - Why unverified: Only the relevant information in the stored summary is recorded; detailed original materials remain unread and review of existing content remains incomplete. Absence of harm tables is not converted to absence of rare harms or long-term safety, and iDFS findings for other drugs do not certify identical harms. No treatment, monitoring or dose recommendations are created. - Reason for missing information: Absence of harm tables is not converted to absence of rare harms or long-term safety, and iDFS findings for other drugs do not certify identical harms. No treatment, monitoring or dose recommendations are created. - Required materials and conditions: Long-term harms, exposure, duration, denominators and direct drug-specific comparisons - Materials to obtain first: Absence of harm tables is not converted to absence of rare harms or long-term safety, and iDFS findings for other drugs do not certify identical harms. No treatment, monitoring or dose recommendations are created. - Further research: Obtain drug-specific direct harm, long-term exposure, collection, denominator and follow-up materials. - Conditions for verification: Long-term harms, exposure, duration, denominators and direct drug-specific comparisons - Why this condition is needed: An individual preparation condition recording the selected claim, comparison, endpoint, denominator, timing and interpretation boundaries - Application exceptions: Unread external materials, other drugs or questions, and outcomes outside the scope do not substitute for fulfillment, zero effect or safety. - Remaining uncertainty: Unread, immature or unverified does not mean zero effect, zero events, safety or a new clinical certification. - Referenced methods: Improved invasive disease-free survival - Related sources: R01, R02, R03, R04, R05 ### N26 · Are original registration, three bibliography URLs and two evidence records without bibliography distinguished? Verification status: Partly verified Reading scope: Summary read; external materials not read - Current findings: The three existing citations provide NATALEE interim and final URLs and a PENELOPE-B URL, while PALLAS and monarchE have only existing evidence-list information. Each original registration identifier is preserved. - Why unverified: Only the relevant information in the stored summary is recorded; detailed original materials remain unread and review of existing content remains incomplete. No new bibliography, DOI or URL is created for PALLAS or monarchE. External abstracts, full texts, registration, protocols and SAP remain unread; separate link testing was not performed. - Reason for missing information: No new bibliography, DOI or URL is created for PALLAS or monarchE. External abstracts, full texts, registration, protocols and SAP remain unread; separate link testing was not performed. - Required materials and conditions: Each report, existing links, registration identifiers and access status - Materials to obtain first: No new bibliography, DOI or URL is created for PALLAS or monarchE. External abstracts, full texts, registration, protocols and SAP remain unread; separate link testing was not performed. - Further research: Connect additional user-provided original materials by report type, bibliography and actual access status. - Conditions for verification: Each report, existing links, registration identifiers and access status - Why this condition is needed: An individual preparation condition recording the selected claim, comparison, endpoint, denominator, timing and interpretation boundaries - Application exceptions: Unread external materials, other drugs or questions, and outcomes outside the scope do not substitute for fulfillment, zero effect or safety. - Remaining uncertainty: Unread, immature or unverified does not mean zero effect, zero events, safety or a new clinical certification. - Referenced methods: Improved invasive disease-free survival - Related sources: R01, R02, R03, R04, R05 ### N27 · Are Korean and English articles, axes, reference dates, corrections, empty values and preparation status preserved? Verification status: Partly verified Reading scope: Summary read; external materials not read - Current findings: 2026-08-26, empty correction and deliberation records, the parent's B76/Caution, axes, Korean and English articles, subclaim B/D and notes are preserved as recorded. - Why unverified: Only the relevant information in the stored summary is recorded; detailed original materials remain unread and review of existing content remains incomplete. Original B0, registration agreement and confirmatory wording are historical records, not new review certification. Subclaim absences are not filled; original pending-review or preparation-eligibility indicators are candidate history. - Reason for missing information: Original B0, registration agreement and confirmatory wording are historical records, not new review certification. Subclaim absences are not filled; original pending-review or preparation-eligibility indicators are candidate history. - Required materials and conditions: Distinguishing the entire parent, selected subclaim, original languages and history from the current preparation - Materials to obtain first: Original B0, registration agreement and confirmatory wording are historical records, not new review certification. Subclaim absences are not filled; original pending-review or preparation-eligibility indicators are candidate history. - Further research: Preserve original texts before connecting additional user materials or decisions as separate events. - Conditions for verification: Distinguishing the entire parent, selected subclaim, original languages and history from the current preparation - Why this condition is needed: An individual preparation condition recording the selected claim, comparison, endpoint, denominator, timing and interpretation boundaries - Application exceptions: Unread external materials, other drugs or questions, and outcomes outside the scope do not substitute for fulfillment, zero effect or safety. - Remaining uncertainty: Unread, immature or unverified does not mean zero effect, zero events, safety or a new clinical certification. - Referenced methods: Improved invasive disease-free survival - Related sources: R01, R02 ## Evidence and sources ### R01 Slamon D, et al. N Engl J Med. 2024;390:1080-1091. PMID: 38507751. [PubMed](https://pubmed.ncbi.nlm.nih.gov/38507751/) Materials actually read: Summary read; external materials not read Findings recorded in the summary: Three-year rates 90.4% versus 87.1%, HR 0.75(95% CI 0.62~0.91), P=.003; final events 226 versus 283, HR 0.749(0.628~0.892), P=.0012 Record level: The two reports from the same NATALEE trial share the integrated evidence-list results; this is not a comparison with each external report Independent replication: The same NATALEE interim and final iDFS reports share a population and two subclaim questions. PALLAS palbociclib contrasts results for another drug and is not independent replication of ribociclib or a direct comparison between drugs. PENELOPE-B palbociclib contrasts results for another drug and is not independent replication of ribociclib or a direct comparison between drugs. monarchE abemaciclib contrasts results for another drug and is not independent replication of ribociclib or a direct comparison between drugs. Family IDs connect report relationships and do not certify independent counts; the same population, sibling questions, follow-up reports and participants receiving other drugs are not newly added as independent observations. | Material | Public availability | Access status | Actually read | Notes | |---|---|---|---|---| | local_summary | Existing link preserved | Summary read | Summary read | Stored parent-verdict summary | | abstract | Existing link preserved | Not read | Not read | External material unread; a URL does not mean acquisition, reading or completed review | | fulltext | No separate URL in the original material | Not read | Not read | External material unread; a URL does not mean acquisition, reading or completed review | | registration | No separate URL in the original material | Not read | Not read | External material unread; a URL does not mean acquisition, reading or completed review | | protocol_sap | No separate URL in the original material | Not read | Not read | External material unread; a URL does not mean acquisition, reading or completed review | ### R02 Hortobagyi GN, et al. Ann Oncol. 2025;36:149-157. PMID: 39442617. [PubMed](https://pubmed.ncbi.nlm.nih.gov/39442617/) Materials actually read: Summary read; external materials not read Findings recorded in the summary: Three-year rates 90.4% versus 87.1%, HR 0.75(95% CI 0.62~0.91), P=.003; final events 226 versus 283, HR 0.749(0.628~0.892), P=.0012 Record level: The two reports from the same NATALEE trial share the integrated evidence-list results; this is not a comparison with each external report Independent replication: The same NATALEE interim and final iDFS reports share a population and two subclaim questions. PALLAS palbociclib contrasts results for another drug and is not independent replication of ribociclib or a direct comparison between drugs. PENELOPE-B palbociclib contrasts results for another drug and is not independent replication of ribociclib or a direct comparison between drugs. monarchE abemaciclib contrasts results for another drug and is not independent replication of ribociclib or a direct comparison between drugs. Family IDs connect report relationships and do not certify independent counts; the same population, sibling questions, follow-up reports and participants receiving other drugs are not newly added as independent observations. | Material | Public availability | Access status | Actually read | Notes | |---|---|---|---|---| | local_summary | Existing link preserved | Summary read | Summary read | Stored parent-verdict summary | | abstract | Existing link preserved | Not read | Not read | External material unread; a URL does not mean acquisition, reading or completed review | | fulltext | No separate URL in the original material | Not read | Not read | External material unread; a URL does not mean acquisition, reading or completed review | | registration | No separate URL in the original material | Not read | Not read | External material unread; a URL does not mean acquisition, reading or completed review | | protocol_sap | No separate URL in the original material | Not read | Not read | External material unread; a URL does not mean acquisition, reading or completed review | ### R03 Loibl S, et al. J Clin Oncol. 2021. PMID: 33793299. [PubMed](https://pubmed.ncbi.nlm.nih.gov/33793299/) Materials actually read: Summary read; external materials not read Findings recorded in the summary: HR 0.93(95% repeated CI 0.74~1.17), P=.525 Record level: Other-drug results in the existing evidence list; not independent replication of ribociclib Independent replication: The same NATALEE interim and final iDFS reports share a population and two subclaim questions. PALLAS palbociclib contrasts results for another drug and is not independent replication of ribociclib or a direct comparison between drugs. PENELOPE-B palbociclib contrasts results for another drug and is not independent replication of ribociclib or a direct comparison between drugs. monarchE abemaciclib contrasts results for another drug and is not independent replication of ribociclib or a direct comparison between drugs. Family IDs connect report relationships and do not certify independent counts; the same population, sibling questions, follow-up reports and participants receiving other drugs are not newly added as independent observations. | Material | Public availability | Access status | Actually read | Notes | |---|---|---|---|---| | local_summary | Existing link preserved | Summary read | Summary read | Stored parent-verdict summary | | abstract | Existing link preserved | Not read | Not read | External material unread; a URL does not mean acquisition, reading or completed review | | fulltext | No separate URL in the original material | Not read | Not read | External material unread; a URL does not mean acquisition, reading or completed review | | registration | No separate URL in the original material | Not read | Not read | External material unread; a URL does not mean acquisition, reading or completed review | | protocol_sap | No separate URL in the original material | Not read | Not read | External material unread; a URL does not mean acquisition, reading or completed review | ### R04 PALLAS palbociclib trial Materials actually read: Summary read; external materials not read Findings recorded in the summary: No added benefit from palbociclib Record level: Other-drug results in the existing evidence list; not independent replication of ribociclib Independent replication: The same NATALEE interim and final iDFS reports share a population and two subclaim questions. PALLAS palbociclib contrasts results for another drug and is not independent replication of ribociclib or a direct comparison between drugs. PENELOPE-B palbociclib contrasts results for another drug and is not independent replication of ribociclib or a direct comparison between drugs. monarchE abemaciclib contrasts results for another drug and is not independent replication of ribociclib or a direct comparison between drugs. Family IDs connect report relationships and do not certify independent counts; the same population, sibling questions, follow-up reports and participants receiving other drugs are not newly added as independent observations. | Material | Public availability | Access status | Actually read | Notes | |---|---|---|---|---| | local_summary | Existing link preserved | Summary read | Summary read | Stored parent-verdict summary | | abstract | No separate URL in the original material | Not read | Not read | External material unread; a URL does not mean acquisition, reading or completed review | | fulltext | No separate URL in the original material | Not read | Not read | External material unread; a URL does not mean acquisition, reading or completed review | | registration | No separate URL in the original material | Not read | Not read | External material unread; a URL does not mean acquisition, reading or completed review | | protocol_sap | No separate URL in the original material | Not read | Not read | External material unread; a URL does not mean acquisition, reading or completed review | ### R05 monarchE abemaciclib trial Materials actually read: Summary read; external materials not read Findings recorded in the summary: Four-year rates 85.8% versus 79.4%, HR 0.664(95% CI 0.578~0.762) Record level: Other-drug results in the existing evidence list; not independent replication of ribociclib Independent replication: The same NATALEE interim and final iDFS reports share a population and two subclaim questions. PALLAS palbociclib contrasts results for another drug and is not independent replication of ribociclib or a direct comparison between drugs. PENELOPE-B palbociclib contrasts results for another drug and is not independent replication of ribociclib or a direct comparison between drugs. monarchE abemaciclib contrasts results for another drug and is not independent replication of ribociclib or a direct comparison between drugs. Family IDs connect report relationships and do not certify independent counts; the same population, sibling questions, follow-up reports and participants receiving other drugs are not newly added as independent observations. | Material | Public availability | Access status | Actually read | Notes | |---|---|---|---|---| | local_summary | Existing link preserved | Summary read | Summary read | Stored parent-verdict summary | | abstract | No separate URL in the original material | Not read | Not read | External material unread; a URL does not mean acquisition, reading or completed review | | fulltext | No separate URL in the original material | Not read | Not read | External material unread; a URL does not mean acquisition, reading or completed review | | registration | No separate URL in the original material | Not read | Not read | External material unread; a URL does not mean acquisition, reading or completed review | | protocol_sap | No separate URL in the original material | Not read | Not read | External material unread; a URL does not mean acquisition, reading or completed review | ## Review criteria and methods These are Chamgap's own application conditions, informed by the relevant sections of official methodological guidance. They do not constitute official assessment-tool certification or a new efficacy score. - M03 [Cochrane Handbook 6.5 (2024), chapter updated 2023-08](https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-03) · §3.1, §3.2.1–3.2.3, MECIR C5/C7/C13 · Clearly record the question, eligibility conditions and reasons for changes, and distinguish variations in interventions. · Preserved methodology connections were reused for preparation. No new review of methodological content, reassessment or external-link checks were performed. - M04 [Cochrane Handbook 6.5.1 (2025), chapter updated 2025-03](https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-04) · §4.5, §4.6.1–4.6.3, MECIR C42 · Distinguish studies from reports and link them; do not omit a study solely because results are unreported. · Preserved methodology connections were reused for preparation. No new review of methodological content, reassessment or external-link checks were performed. - M08 [Cochrane Handbook 6.5 (2024), chapter updated 2019-10](https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-08) · §8.1–8.2.3, Table 8.2.a · Define the outcome and effect of interest, then examine randomization, deviations, missing data, measurement and selective reporting. · Preserved methodology connections were reused for preparation. No new review of methodological content, reassessment or external-link checks were performed. - M15 [Cochrane Handbook 6.5 (2024), chapter updated 2023-08](https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-15) · §15.2.4, §15.3.1–15.3.3 · Distinguish effect estimates, intervals, importance and applicability. Sample size alone does not determine precision. · Preserved methodology connections were reused for preparation. No new review of methodological content, reassessment or external-link checks were performed. - M19 [Cochrane Handbook 6.5 (2024), chapter updated 2019-10](https://www.cochrane.org/authors/handbooks-and-manuals/handbook/current/chapter-19) · §19.1.2, §19.2.1–19.2.4 · Harm questions may require different designs, populations and follow-up from efficacy questions. Case reports do not establish incidence rates. · Preserved methodology connections were reused for preparation. No new review of methodological content, reassessment or external-link checks were performed. ## What the statuses mean - Partly verified: Some information exists in the preserved review summary, with detailed original materials still unverified; no certification of a passed review or clinical efficacy - Unverified: Detailed materials for the selected condition could not be established within the stored scope; this does not mean zero effect, zero studies or safety - Review incomplete: Existing content review pending - Met: Use only within the relevant conditions after existing content review; no automatic designation in this preparation - Not reported: Distinguish only within materials actually read; do not turn unread external materials into unreported findings - Inaccessible: Not applied during this preparation because actual access was not tested - Not applicable: Use with a reason for non-applicability based on an explicit question boundary - Conflicting data: Judge after actual material comparison; review was not performed during this preparation - Insufficient evidence for the conditions: Do not use as a clinical grade encompassing currently unread materials ## Change history 2026-10-10 · Public page/materials 1.0. Public pages and materials were prepared from the existing 27 items. No new clinical search, verification-status change or scoring was performed.